Cargando…

Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open‐label, long‐term safety and tolerability study

OBJECTIVES: The objective of this study was to evaluate the long‐term safety and tolerability of flexible‐dose brexpiprazole adjunct to antidepressant treatment (ADT) in elderly patients with major depressive disorder (MDD). METHODS: Elderly patients (≥65 years) with MDD and inadequate response to ≥...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lepola, Ulla, Hefting, Nanco, Zhang, Doris, Hobart, Mary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175103/ https://www.ncbi.nlm.nih.gov/pubmed/30039634 http://dx.doi.org/10.1002/gps.4952

Ejemplares similares

A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
por: Hobart, Mary, et al.
Publicado: (2019)

Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies
por: Marder, Stephen R, et al.
Publicado: (2021)

Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial
por: Lee, Daniel, et al.
Publicado: (2023)

Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania
por: Vieta, Eduard, et al.
Publicado: (2021)

A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia
por: Forbes, Andy, et al.
Publicado: (2018)

Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale
por: Hobart, Mary, et al.
Publicado: (2018)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study
por: Davis, Lori L., et al.
Publicado: (2016)

Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression
por: Bruijnzeel, Dawn, et al.
Publicado: (2016)

Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning
por: Fava, Maurizio, et al.
Publicado: (2016)

Effect of Brexpiprazole on Prolactin and Sexual Functioning: An Analysis of Short- and Long-Term Study Data in Major Depressive Disorder
por: Clayton, Anita H., et al.
Publicado: (2020)

Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder
por: Seetasith, Arpamas, et al.
Publicado: (2019)

PS152. Efficacy and safety of brexpiprazole (OPC-34712) as adjunctive treatment in major depressive disorder: Meta-analysis of two pivotal studies
por: Eriksson, Hans, et al.
Publicado: (2016)

PS155. Long-term safety of adjunctive brexpiprazole (OPC-34712) in MDD: results from two 52-week open-label studies
por: Nelson, Craig, et al.
Publicado: (2016)

PS151. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and anxiety symptoms: an exploratory study
por: Davis, Lori, et al.
Publicado: (2016)

Long-Term Efficacy and Safety of Brexpiprazole in Elderly Japanese Patients with Schizophrenia: A Subgroup Analysis of an Open-Label Study
por: Inada, Ken, et al.
Publicado: (2020)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies
por: Thase, Michael E, et al.
Publicado: (2018)

Efficacy of Brexpiprazole as Adjunctive Treatment in Major Depressive Disorder With Irritability: Post Hoc Analysis of 2 Pivotal Clinical Studies
por: Fava, Maurizio, et al.
Publicado: (2017)

PS156. Adjunctive brexpiprazole, a novel effective strategy for treating Major depressive disorder?: Systematic review and Meta-analysis
por: Yoon, Seoyoung, et al.
Publicado: (2016)

Effect of Brexpiprazole on Prolactin: An Analysis of Short- and Long-Term Studies in Schizophrenia
por: Ivkovic, Jelena, et al.
Publicado: (2019)

Clinical role of brexpiprazole in depression and schizophrenia
por: Parikh, Nishant B, et al.
Publicado: (2017)

O7.5. LONG-TERM SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN PATIENTS WITH SCHIZOPHRENIA
por: Hakala, Mika, et al.
Publicado: (2018)

Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder
por: Vieta, Eduard, et al.
Publicado: (2019)

Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis
por: Kishi, Taro, et al.
Publicado: (2019)

Brexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder
por: Diefenderfer, Lauren A., et al.
Publicado: (2018)

Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study
por: Ishigooka, Jun, et al.
Publicado: (2021)

Effects of adjunctive brexpiprazole on sleep-wake and circadian parameters in youth with depressive disorders: study protocol for a clinical trial
por: Carpenter, Joanne S, et al.
Publicado: (2022)

The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies
por: Weiss, Catherine, et al.
Publicado: (2018)

Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews
por: Weiss, Catherine, et al.
Publicado: (2021)

Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients < 16 Years with Epilepsy: An Open-Label Trial
por: Liu, Edwin, et al.
Publicado: (2019)

Open-label placebos as adjunctive therapy for patients with depression
por: Schienle, Anne, et al.
Publicado: (2022)

PM385. Long-term safety of brexpiprazole (OPC-34712) in schizophrenia: results from two 52-week open-label studies
por: Correll, Christoph U., et al.
Publicado: (2016)

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
por: Berman, Robert M, et al.
Publicado: (2011)

Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study
por: Fleischhacker, W. Wolfgang, et al.
Publicado: (2016)

Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder
por: Martinez, James M, et al.
Publicado: (2015)

Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies
por: Weiller, Emmanuelle, et al.
Publicado: (2017)

Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
por: Mago, Rajnish, et al.
Publicado: (2013)

A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults
por: Richards, Cynthia, et al.
Publicado: (2018)

Efficacy and tolerability of brexpiprazole in patients with psychotic and mood disorders: a pilot study
por: Civardi, S.C., et al.
Publicado: (2022)

Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
por: Wade, Alan G, et al.
Publicado: (2011)

Erratum to: Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
por: Mago, Rajnish, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3ca8324n04bquhbg8rs8u88dsj